MACC1-DT: A Potential Drug Target and Biomarker (G100506098)

Target Name: MACC1-DT

NCBI ID: G100506098

MACC1-DT

Other Name(s): MACC1 divergent transcript, transcript variant 1 | MACC1 divergent transcript | MACC1-DT variant 1

MACC1-DT: A Potential Drug Target and Biomarker

Malignant cells, also known as cancer cells, are a leading cause of death worldwide. These cells have the ability to continuously divide and proliferate, leading to the formation of tumors. One of the main challenges in cancer treatment is the development of resistance to drugs, which can limit the effectiveness of these treatments. To address this issue, researchers have been investigating new drug targets and biomarkers that can help identify and treat cancer at an early stage. In this article, we will focus on MACC1-DT, a potential drug target and biomarker for cancer treatment.

MACC1 (Malignant Alkaline Composition of Cells) is a protein that is expressed in various types of cancer cells. It is highly expressed in human breast, ovarian, and colorectal cancer, and its expression has been associated with cancer progression and poor prognosis. MACC1 has been shown to play a role in the development and metastasis of various types of cancer.

One of the main functions of MACC1 is its role in cell signaling. MACC1 functions as a negative regulator of the TGF-β pathway, which is a well-known pathway that plays a role in cell growth, differentiation, and survival. The TGF-β pathway is involved in many cellular processes, including cell proliferation, migration, and angiogenesis. By regulating the TGF-β pathway, MACC1 has been shown to contribute to the development of cancer.

MACC1 has also been shown to play a role in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. MACC1 has been shown to regulate the stickiness of cancer cells to surrounding cells, which is a key step in the development of cancer.

In addition to its role in cell signaling and adhesion, MACC1 has also been shown to play a role in the regulation of cell survival. Cancer cells have a higher ability to survive than normal cells because they are able to continuously divide and proliferate. MACC1 has been shown to play a role in regulating the cell cycle, by preventing the rapid division of cancer cells.

MACC1 is also a potential biomarker for cancer diagnosis and treatment. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that MACC1 may be a useful biomarker for the diagnosis and treatment of cancer.

One of the main potential drug targets for MACC1 is its role in cell signaling. MACC1 has been shown to play a negative role in the TGF-β pathway, which is a well-known pathway that plays a role in cell growth, differentiation, and survival. By inhibiting the TGF-β pathway, MACC1 may be a useful drug target for cancer treatment.

MACC1 has also been shown to play a role in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. MACC1 has been shown to regulate the stickiness of cancer cells to surrounding cells, which may be a useful target for cancer treatments that aim to disrupt cell adhesion.

In addition to its potential drug target and biomarker properties, MACC1 also has potential as a therapeutic approach for cancer treatment. Studies have shown that inhibiting MACC1 may be effective in treating various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that MACC1 may be a useful target for cancer therapy.

In conclusion, MACC1-DT is a potential drug target and biomarker for cancer treatment. Its role in cell signaling, cell adhesion, and cell survival suggests that it may be a useful target for cancer therapies that aim to inhibit these processes. Further research is needed to

Protein Name: MACC1 Divergent Transcript

The "MACC1-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MACC1-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets